Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US7612162B2 · kind B2 · utility
18Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2005 |
| Grant date | Nov 3, 2009 |
| Priority date | — |
| Expiry date | Sep 21, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/572
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.